ABSTRACT
The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease management. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for SCLC regarding immunotherapy, systemic therapy, and radiation therapy. For the 2018 update, new sections were added on "Signs and Symptoms of SCLC" and "Principles of Pathologic Review."
Subject(s)
Brain Neoplasms/prevention & control , Lung Neoplasms/therapy , Medical Oncology/standards , Small Cell Lung Carcinoma/therapy , Antineoplastic Agents, Immunological/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Brain Neoplasms/secondary , Chemoradiotherapy/methods , Chemoradiotherapy/standards , Cranial Irradiation/methods , Cranial Irradiation/standards , Dose-Response Relationship, Radiation , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/pathology , Medical Oncology/methods , Neoplasm Staging , Pneumonectomy/methods , Pneumonectomy/standards , Radiotherapy Dosage , Randomized Controlled Trials as Topic , Small Cell Lung Carcinoma/diagnosis , Small Cell Lung Carcinoma/mortality , Small Cell Lung Carcinoma/secondary , Societies, Medical/standards , Survival Analysis , Treatment Outcome , United StatesABSTRACT
This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management of advanced disease with radiation and systemic therapy. Included in these sections are discussion of the new recommendations for use of Merkel cell polyomavirus as a biomarker and new recommendations for use of checkpoint immunotherapies to treat metastatic or unresectable disease. The next update of the complete version of the NCCN Guidelines for MCC will include more detailed information about elements of pathology and addresses additional aspects of management of MCC, including surgical management of the primary tumor and draining nodal basin, radiation therapy as primary treatment, and management of recurrence.
Subject(s)
Carcinoma, Merkel Cell/therapy , Medical Oncology/standards , Merkel cell polyomavirus/isolation & purification , Skin Neoplasms/therapy , Aftercare/standards , Carcinoma, Merkel Cell/diagnosis , Carcinoma, Merkel Cell/epidemiology , Carcinoma, Merkel Cell/virology , Chemoradiotherapy/methods , Chemoradiotherapy/standards , Humans , Incidence , Skin Neoplasms/diagnosis , Skin Neoplasms/virology , Societies, Medical/standards , United States/epidemiologyABSTRACT
The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E-mutated anaplastic thyroid carcinoma.
Subject(s)
Carcinoma/therapy , Medical Oncology/standards , Thyroid Neoplasms/therapy , Antineoplastic Combined Chemotherapy Protocols/standards , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/analysis , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Carcinoma/diagnosis , Carcinoma/mortality , Carcinoma/pathology , Clinical Trials as Topic , Humans , Image-Guided Biopsy/methods , Image-Guided Biopsy/standards , Neoplasm Staging , Prognosis , Protein Kinase Inhibitors/standards , Protein Kinase Inhibitors/therapeutic use , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Proto-Oncogene Proteins B-raf/genetics , Societies, Medical/standards , Thyroid Gland/diagnostic imaging , Thyroid Gland/pathology , Thyroid Gland/surgery , Thyroid Neoplasms/diagnosis , Thyroid Neoplasms/genetics , Thyroid Neoplasms/pathology , Thyroidectomy/methods , Thyroidectomy/standards , Treatment Outcome , United StatesABSTRACT
The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma.
Subject(s)
Carcinoma, Hepatocellular/therapy , Liver Neoplasms/therapy , Humans , United StatesABSTRACT
Infectious diseases are important causes of morbidity and mortality in patients with cancer. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections characterize the major pathogens to which patients with cancer are susceptible, with a focus on the prevention, diagnosis, and treatment of major common and opportunistic infections. This portion of the guidelines highlights the sections on antifungal and antiviral prophylaxis. Antifungal and antiviral prophylaxis recommendations have expanded over the past few years. New agents for the treatment of fungal infections and incorporation of therapeutic drug monitoring are presented. Antiviral prophylaxis for hepatitis B and management considerations for hepatitis C and HIV have been further developed.
Subject(s)
Communicable Diseases/therapy , Neoplasms/complications , Neoplasms/therapy , HumansABSTRACT
Basal cell carcinoma (BCC) of the skin is the most common cancer, with a higher incidence than all other malignancies combined. Although it is rare to metastasize, patients with multiple or frequently recurring BCC can suffer substantial comorbidity and be difficult to manage. Assessment of risk is a key element of management needed to inform treatment selection. The overall management of BCC primarily consists of surgical approaches, with radiation therapy as an alternate or adjuvant option. Many superficial therapies for BCC have been explored and continue to be developed, including topicals, cryosurgery, and photodynamic therapy. Two hedgehog pathway inhibitors were recently approved by the FDA for systemic treatment of advanced and metastatic BCC, and others are in development. The NCCN Guidelines for Basal Cell Skin Cancer, published in full herein, include recommendations for selecting among the various surgical approaches based on patient-, lesion-, and disease-specific factors, as well as guidance on when to use radiation therapy, superficial therapies, and hedgehog pathway inhibitors.
Subject(s)
Carcinoma, Basal Cell , Skin Neoplasms , Humans , Carcinoma, Basal Cell/diagnosis , Carcinoma, Basal Cell/therapy , Skin Neoplasms/diagnosis , Skin Neoplasms/therapy , United StatesABSTRACT
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.
Subject(s)
Thyroid Carcinoma, Anaplastic/diagnosis , Thyroid Carcinoma, Anaplastic/therapy , Thyroid Neoplasms/diagnosis , Thyroid Neoplasms/therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carboplatin/administration & dosage , Docetaxel , Doxorubicin/administration & dosage , Humans , Paclitaxel/administration & dosage , Radiotherapy, Intensity-Modulated , Taxoids/administration & dosage , Thyroid Carcinoma, Anaplastic/secondary , Thyroid Neoplasms/pathology , ThyroidectomyABSTRACT
These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.
Subject(s)
Adenocarcinoma/drug therapy , Protein Kinase Inhibitors/therapeutic use , Thyroid Neoplasms/drug therapy , Adenocarcinoma/pathology , Anilides/therapeutic use , Carcinoma, Neuroendocrine , Guidelines as Topic , Humans , Neoplasm Metastasis , Niacinamide/analogs & derivatives , Niacinamide/therapeutic use , Phenylurea Compounds/therapeutic use , Pyridines/therapeutic use , Sorafenib , Thyroid Neoplasms/pathologyABSTRACT
Hepatobiliary cancers include a spectrum of invasive carcinomas arising in the liver (hepatocellular carcinoma), gall bladder, and bile ducts (cholangiocarcinomas). Gallbladder cancer and cholangiocarcinomas are collectively known as biliary tract cancers. Gallbladder cancer is the most common and aggressive type of all the biliary tract cancers. Cholangiocarcinomas are diagnosed throughout the biliary tree and are typically classified as either intrahepatic or extrahepatic cholangiocarcinoma. Extrahepatic cholangiocarcinomas are more common than intrahepatic cholangiocarcinomas. This manuscript focuses on the clinical management of patients with gallbladder cancer and cholangiocarcinomas (intrahepatic and extrahepatic).
Subject(s)
Bile Duct Neoplasms/therapy , Carcinoma, Hepatocellular/therapy , Cholangiocarcinoma/therapy , Gallbladder Neoplasms/therapy , Bile Duct Neoplasms/epidemiology , Bile Duct Neoplasms/pathology , Bile Ducts, Intrahepatic/pathology , Carcinoma, Hepatocellular/pathology , Cholangiocarcinoma/epidemiology , Cholangiocarcinoma/pathology , Gallbladder Neoplasms/epidemiology , Gallbladder Neoplasms/pathology , Guidelines as Topic , Humans , Liver Neoplasms/pathology , Liver Neoplasms/therapy , Randomized Controlled Trials as TopicABSTRACT
Merkel cell carcinoma is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative nonmelanoma skin cancer with the regional and distant metastatic rates of thick melanoma. The NCCN Guidelines for Merkel Cell Carcinoma provide recommendations on the diagnosis and management of this aggressive disease based on clinical evidence and expert consensus. This version includes revisions regarding the use of PET/CT imaging and the addition of a new section on the principles of pathology to provide guidance on the analysis, interpretation, and reporting of pathology results.